Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMp Up real-world effectiveness study in atopic dermatitis
NL-OMON61530Phase 4Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of upadacitinib, tralokinumab, dupilumab, lebrikizumab and nemolizumab in atopic dermatitis (AD) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Achievement of minimal disease activity at week 16. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON61530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61530.